Tourmaline Bio Stock (NASDAQ:TRML)
Previous Close
$47.98
52W Range
$11.56 - $48.27
50D Avg
$40.68
200D Avg
$22.74
Market Cap
$1.23B
Avg Vol (3M)
$925.78K
Beta
1.58
Div Yield
-
TRML Company Profile
Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.